Addex Therapeutics (ADXN) Thursday said it got back all rights to ADX71149 following its termination of partnership with Janssen Pharmaceuticals, Inc.
Addex had previously announced that its partner Janssen discontinued development of ADX71149 after Phase 2 study of the drug candidate evaluating as an adjunctive epilepsy treatment failed to achieve primary goal.
"ADX71149 is a high quality asset which has completed three Phase 2 studies so we are excited to regain control of its development from our partner with its high quality data package and significant material. We are evaluating a number of high value therapeutic indications for the future development of the program as well as pursuing discussions with a number of potential partners for the program", said Tim Dyer, CEO of Addex.
For comments and feedback: editorial@rttnews.com